Delivery Order SPE2DR25D1109-SPE2DR26FFJ1D
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL) with a ceiling value of $1,588.97. This competitively awarded, non-set-aside contract was executed on December 3, 2025, with an ultimate completion date of December 4, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls under the company's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,721.55 for Quillivant XR 25 mg/5 ml suspension (150 ml) with a firm fixed price structure. The award was made on December 5, 2025, with an ultimate completion date of December 8, 2025. This non-set-aside contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its headquarters as a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 20, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $1,526.88. This non-set-aside, firm fixed-price delivery order is scheduled for completion by November 21, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,978.37 for Quillivant XR 25 mg/5 ml suspension (60 ml) with a firm fixed price structure. This non-set-aside, competitively awarded contract was executed on September 9, 2025, with an ultimate completion date of September 10, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL) with a ceiling value of $2,328.26 on December 1, 2025, with ultimate completion scheduled for December 2, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension (150 mL) with a ceiling value of $1,269.76. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for ultimate completion by November 6, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) with a ceiling value of $2,079.82. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 17, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a $4,127.17 delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL). This firm fixed-price delivery order, with an ultimate completion date of December 3, 2025, represents a continuation of AmerisourceBergen's critical role as a pharmaceutical supplier to the Department of Defense medical supply chain. The contract was competitively awarded without set-aside designation and will be...
- The Defense Logistics Agency awarded a delivery order valued at $2,050.33 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL) on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,139.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for Quillivant XR 25 mg/5 ml suspension (60 ml), with an ultimate completion date of December 12, 2025. This non-set-aside delivery order is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order leverages AmerisourceBergen's Indefinite Delivery Contract (IDC) with...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFJ1DDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (60 mL) with a ceiling value of $4,550.04. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, was executed on December 16, 2025, with an ultimate completion date of December 17, 2025. The place of performance is located in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle valued through December 2026 that serves as a comprehensive global pharmaceutical support contract. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and other government healthcare providers. The company's extensive federal contract portfolio demonstrates its capability to deliver a comprehensive range of pharmaceutical products across multiple therapeutic domains, including brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities. The Quillivant XR delivery, an ADHD medication commonly used in pediatric and adult populations, represents a routine execution under the company's expansive DLA pharmaceutical supply contract that enables flexible sourcing of medical commodities to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 12/15/25 |